

Emergent BioSolutions Inc.  
Form 8-K  
February 04, 2014  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 29, 2014

Emergent BioSolutions Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware 001-33137 14-1902018

(State or Other Jurisdiction (Commission (IRS Employer  
of Incorporation) File Number) Identification No.)

2273 Research Boulevard, Suite 400, 20850  
Rockville, Maryland

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (301) 795-1800

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01 Other Events.

On January 29, 2014, Emergent BioSolutions Inc. announced the completion of its offering of \$250 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 and that it intends to use a majority of the net proceeds to finance the company's acquisition of Cangene Corporation. In connection with the company's issuance of the notes, the unused \$125 million term loan portion of the company's credit facility terminated automatically in accordance with the terms of the senior secured credit agreement, dated December 11, 2013, with Bank of America, N.A., as administrative agent. In addition, following the closing of the notes offering, the company repaid the \$62 million outstanding indebtedness under the revolving credit portion of the credit facility, which restored the full \$100 million revolving credit capacity under this facility. The company intends to use any remaining net proceeds from the notes offering for general corporate purposes.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 29, 2014 EMERGENT BIOSOLUTIONS INC.

/s/ Robert G. Kramer

By: Robert G. Kramer

Executive Vice President and Chief Financial Officer